Search

everythinglearnresearchcommunity

for

Search:↓

CLASI is a valid tool for assessing skin activity and damage in lupus patients.

Hair loss can indicate or worsen with systemic diseases, and treating the underlying condition is important.

Hair loss is common in lupus patients and can be permanent or reversible, depending on the type, with various treatments available.

Lower GPX4 mRNA levels are linked to higher disease activity and symptoms in lupus patients.

Hair loss in SLE patients is mostly due to chronic telogen effluvium and is linked to moderate disease activity.

Chinese patients with systemic lupus erythematosus commonly experience oral ulcers, arthritis, alopecia, skin rash, and nephritis.

Trichoscopy is useful for diagnosing and monitoring systemic lupus erythematosus, with certain hair and scalp changes indicating more active disease.

Higher disease activity in systemic lupus erythematosus is strongly linked to more internal organ damage.

Skin problems are common in lupus patients and should be treated early to prevent worsening.

Tph cells are linked to the severity of systemic lupus erythematosus.

Most Korean systemic lupus erythematosus patients experienced hair loss, often as non-scarring diffuse hair loss, with non-scarring patch alopecia also common.

Hair loss in lupus is different from hair loss in alopecia areata and may indicate lupus activity.

About 8% of people with systemic lupus erythematosus have chronic scarring alopecia, with certain symptoms and positive antibodies increasing the risk, while immunosuppressants may lower it.

Most lupus patients in the study experienced hair loss, which greatly affected their mental and social well-being.

Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.

Hair loss in lupus patients indicates higher disease activity.

Non-scarring hair loss in lupus patients often responds well to treatment and doesn't lead to scarring.

Early treatment of Lupus Erythematosus Alopecia can prevent permanent hair loss, and various medications are effective.

Non-scarring hair loss is common in lupus patients and can be diagnosed with specific hair and tissue tests.

Tofacitinib is a promising treatment for children with rheumatic diseases.

Certain skin symptoms can help detect and manage systemic lupus.

The CLASI is a reliable tool for measuring the severity of cutaneous lupus erythematosus.

Belimumab effectively controls SLE disease activity and reduces steroid use.

Skin problems are common in Lupus patients and can indicate the disease's severity, requiring specific treatments and lifestyle changes.

Hair chemicals don't cause SLE but may increase skin issues in those with SLE.

Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.

An imbalance in gut bacteria is linked to skin immune diseases and may affect their outcomes and related health issues.

The mtDNA N haplogroup is linked to a higher risk of late-onset lupus and specific symptoms in Han Chinese women.

Environmental factors like diet and vitamin levels, especially Vitamin D, can affect autoimmune diseases differently, with lifestyle changes potentially improving outcomes.

Diagnosing both systemic lupus and hemoglobinopathy is challenging due to overlapping symptoms.